Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill
them or deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy such as carboplatin work in different ways to stop tumor cells from dividing so
they stop growing or die. Combining cetuximab with carboplatin may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving cetuximab together with carboplatin
works in treating patients with recurrent ovarian epithelial cancer or primary peritoneal
cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Gynecologic Oncology Group
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)